DealsMay 14, 2026, 08:32 AM
MeiraGTx Secures Lilly, Hologen Collaborations; Reacquires RPGR Product
AI Summary
MeiraGTx Holdings plc announced significant strategic developments, including a collaboration with Eli Lilly and Company for ophthalmology gene therapies, providing $75.0 million upfront and up to $400.0 million in milestones. The company also entered a strategic collaboration with Hologen Limited for CNS gene therapies, involving a $200.0 million upfront payment commitment. Additionally, MeiraGTx reacquired the RPGR Product from Janssen Pharmaceuticals for an upfront cash purchase price of $25.0 million. For Q1 2026, the company reported a net loss of $(46.3) million, with total revenue of $0.293 million.
Key Highlights
- Secured Eli Lilly collaboration with $75.0 million upfront and up to $400.0 million in milestones.
- Entered strategic collaboration with Hologen for CNS gene therapies, with a $200.0 million upfront commitment.
- Reacquired the RPGR Product from Janssen Pharmaceuticals for an upfront cash purchase price of $25.0 million.
- Reported a Q1 2026 net loss of $(46.3) million, compared to $(39.9) million in Q1 2025.
- Total revenue for Q1 2026 was $0.293 million, a decrease from $1.926 million year-over-year.
- Research and development expenses were $31.984 million for the three months ended March 31, 2026.
- Cash, cash equivalents, and restricted cash totaled $73.8 million as of March 31, 2026.
- Total Shareholders' Deficit increased to $(58.130) million from $(5.793) million at December 31, 2025.